WO2023177376A3 - The use of the molecule hydroquinidine in the treatment of brain tumors - Google Patents

The use of the molecule hydroquinidine in the treatment of brain tumors Download PDF

Info

Publication number
WO2023177376A3
WO2023177376A3 PCT/TR2023/050230 TR2023050230W WO2023177376A3 WO 2023177376 A3 WO2023177376 A3 WO 2023177376A3 TR 2023050230 W TR2023050230 W TR 2023050230W WO 2023177376 A3 WO2023177376 A3 WO 2023177376A3
Authority
WO
WIPO (PCT)
Prior art keywords
hydroquinidine
molecule
treatment
brain tumors
tumors
Prior art date
Application number
PCT/TR2023/050230
Other languages
French (fr)
Other versions
WO2023177376A2 (en
Inventor
Turan DEMIRCAN
Mervenur YAVUZ
Original Assignee
Mugla Sitki Kocman Universitesi Idari Mali Isler Baskanligi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2022/004099 external-priority patent/TR2022004099A2/en
Application filed by Mugla Sitki Kocman Universitesi Idari Mali Isler Baskanligi filed Critical Mugla Sitki Kocman Universitesi Idari Mali Isler Baskanligi
Publication of WO2023177376A2 publication Critical patent/WO2023177376A2/en
Publication of WO2023177376A3 publication Critical patent/WO2023177376A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the use of the molecule hydroquinidine as a drug candidate for the treatment of brain cancer and tumors and the relief of symptoms resulting from these diseases. The invention also discloses in vitro studies carried out by the inventors in this direction.
PCT/TR2023/050230 2022-03-17 2023-03-08 The use of the molecule hydroquinidine in the treatment of brain tumors WO2023177376A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2022004099 2022-03-17
TR2022/004099 TR2022004099A2 (en) 2022-03-17 USE OF HYDROKINIDINE MOLECULE IN THE TREATMENT OF BRAIN TUMORS

Publications (2)

Publication Number Publication Date
WO2023177376A2 WO2023177376A2 (en) 2023-09-21
WO2023177376A3 true WO2023177376A3 (en) 2023-11-09

Family

ID=88023761

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2023/050230 WO2023177376A2 (en) 2022-03-17 2023-03-08 The use of the molecule hydroquinidine in the treatment of brain tumors

Country Status (1)

Country Link
WO (1) WO2023177376A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635515A (en) * 1991-02-15 1997-06-03 Debiopharm S.A. Therapeutic agents for the treatment of multiple drug resistance of cancers
KR20210007066A (en) * 2019-07-09 2021-01-20 충남대학교산학협력단 Adjuvant for anti-cancer containing quinidine derivatives as an active ingredient
WO2022051495A1 (en) * 2020-09-02 2022-03-10 Ann And Robert H. Lurie Children's Hospital Of Chicago Methods and compositions for the treatment of pulmonary hypertension and cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635515A (en) * 1991-02-15 1997-06-03 Debiopharm S.A. Therapeutic agents for the treatment of multiple drug resistance of cancers
KR20210007066A (en) * 2019-07-09 2021-01-20 충남대학교산학협력단 Adjuvant for anti-cancer containing quinidine derivatives as an active ingredient
WO2022051495A1 (en) * 2020-09-02 2022-03-10 Ann And Robert H. Lurie Children's Hospital Of Chicago Methods and compositions for the treatment of pulmonary hypertension and cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
E SOLARY , I VELAY, B CHAUFFERT, J M BIDAN, D CAILLOT, M DUMAS, H GUY: "Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM", CANCER, vol. 68, no. 8, 15 October 1991 (1991-10-15), US , pages 1714 - 1719, XP002587817, ISSN: 0008-543X, DOI: 10.1002/1097-0142(19911015)68:8<1714::aid-cncr2820680811>3.0.co;2-2 *

Also Published As

Publication number Publication date
WO2023177376A2 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
EA200601494A1 (en) IMIDAZOLIC CONNECTIONS FOR THE TREATMENT OF NEURODEGERATIVE DISORDERS
PH12019500214A1 (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
WO2021021979A3 (en) Hdac6 inhibitors and uses thereof
PH12018550049A1 (en) Protein kinase inhibitor, preparation method and medical use thereof
BR0315158A (en) Pyrazole Compounds for the Treatment of Neurodegenative Disorders
CA2501651A1 (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
Tevyashova et al. Modification of olivomycin A at the side chain of the aglycon yields the derivative with perspective antitumor characteristics
CA2464758A1 (en) Combination therapy comprising zd6474 and a taxane
NO20034031L (en) Substituted pyrazole and thiazole pyrimidines
WO2010076033A9 (en) Toluidine sulfonamides and their use
MX2021010568A (en) Leucine, acetyl leucine, and related analogs for treating disease.
US20200323814A1 (en) Medical compound
WO2020231739A3 (en) Compounds and methods for treating cancer
WO2023177376A3 (en) The use of the molecule hydroquinidine in the treatment of brain tumors
EA200800659A1 (en) CONNECTIONS OF IMIDAZOL FOR THE TREATMENT OF NEUROLOGICAL DISTURBANCES
CR20230177A (en) Compounds and compositions as modulators of tlr signaling
WO2021242844A8 (en) Grk2 inhibitors and uses thereof
WO2023205595A3 (en) Egfr inhibitors in cancer treatment
WO2019195207A1 (en) Light-activated cannabinoid compounds and methods of use thereof
WO2023122782A3 (en) Indoles, indazoles, and related analogs for inhibiting yap/taz-tead
IL274067B2 (en) Kinase inhibitors for the treatment of central and peripheral nervous system disorders
WO2023081482A9 (en) Combination of a bile acid and a phenyl butyrate compound for the treatment of neurodegenerative diseases
MX2023013149A (en) Anti-il-27 antibodies and uses thereof.
WO2021099966A3 (en) Novel benzothiophene derivatives and use thereof for stimulating mitochondrial turnover
WO2021262910A3 (en) Tubulysins and protein-tubulysin conjugates

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23771189

Country of ref document: EP

Kind code of ref document: A2